These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 9630922)

  • 1. Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation.
    Zhang X; Piatier-Tonneau D; Auffray C; Murali R; Mahapatra A; Zhang F; Maier CC; Saragovi H; Greene MI
    Nat Biotechnol; 1996 Apr; 14(4):472-5. PubMed ID: 9630922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes.
    Zhang X; Gaubin M; Briant L; Srikantan V; Murali R; Saragovi U; Weiner D; Devaux C; Autiero M; Piatier-Tonneau D; Greene MI
    Nat Biotechnol; 1997 Feb; 15(2):150-4. PubMed ID: 9035140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profound enhancement of T cell activation mediated by the interaction between the TCR and the D3 domain of CD4.
    Vignali DA; Vignali KM
    J Immunol; 1999 Feb; 162(3):1431-9. PubMed ID: 9973399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin superfamily proteins: structure, mechanisms, and drug discovery.
    Huang Z; Li S; Korngold R
    Biopolymers; 1997; 43(5):367-82. PubMed ID: 9566118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of liposomes to HIV-1-infected cells by peptides derived from the CD4 receptor.
    Slepushkin VA; Salem II; Andreev SM; Dazin P; Düzgüneş N
    Biochem Biophys Res Commun; 1996 Oct; 227(3):827-33. PubMed ID: 8886017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic peptides of human CD4 enhance binding of Ig to monocyte/macrophage cells. I. Characterization and mapping studies.
    Lenert P; Mehta RL; Zanetti M
    J Immunol; 1992 Mar; 148(6):1759-63. PubMed ID: 1541816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A site for CD4 binding in the beta 1 domain of the MHC class II protein HLA-DR1.
    Brogdon J; Eckels DD; Davies C; White S; Doyle C
    J Immunol; 1998 Nov; 161(10):5472-80. PubMed ID: 9820523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor.
    Li Y; Ishiyama S; Matsueda S; Tsuda N; Ioannides CG
    Oncol Rep; 2008 Jun; 19(6):1445-52. PubMed ID: 18497949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis.
    Burrows GG; Bebo BF; Adlard KL; Vandenbark AA; Offner H
    J Immunol; 1998 Dec; 161(11):5987-96. PubMed ID: 9834080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for the interaction between focal adhesion kinase and CD4.
    Garron ML; Arthos J; Guichou JF; McNally J; Cicala C; Arold ST
    J Mol Biol; 2008 Feb; 375(5):1320-8. PubMed ID: 18078954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The orientation and nature of the interaction between beef insulin-specific TCRs and the insulin/class II MHC complex.
    Wither JE; Vukusic B
    J Immunol; 1999 Feb; 162(4):2113-22. PubMed ID: 9973485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synthetic CD4 exocyclic CDR3.AME(82-89) inhibits NF-kappaB nuclear translocation, HIV-1 promoter activation, and viral gene expression.
    Roland J; Berezov A; Greene MI; Murali R; Piatier-Tonneau D; Devaux C; Briant L
    DNA Cell Biol; 1999 Nov; 18(11):819-28. PubMed ID: 10595395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR studies on the conformation of the CD4 36-59 peptide bound to HIV-1 gp120.
    Gizachew D; Moffett DB; Busse SC; Westler WM; Dratz EA; Teintze M
    Biochemistry; 1998 Jul; 37(30):10616-25. PubMed ID: 9692951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minor structural changes in a mutated human melanoma antigen correspond to dramatically enhanced stimulation of a CD4+ tumor-infiltrating lymphocyte line.
    Sundberg EJ; Sawicki MW; Southwood S; Andersen PS; Sette A; Mariuzza RA
    J Mol Biol; 2002 May; 319(2):449-61. PubMed ID: 12051920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic peptides mapping to epitopes of the extracellular domain of the interleukin-2 receptor beta-chain to inhibit T-cell activation.
    Parissi T; Chatzantoni K; Deraos S; Matsoukas I; Mouzaki A
    Transplant Proc; 2004; 36(6):1723-7. PubMed ID: 15350462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct involvement of the CDR3-like domain of CD4 in T helper cell activation.
    McDonnell JM; Blank KJ; Rao PE; Jameson BA
    J Immunol; 1992 Sep; 149(5):1626-30. PubMed ID: 1387146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Th cells and Th2 responses can develop in the absence of MHC class II-CD4 interactions.
    Wack A; Corbella P; Harker N; Roderick K; Norton T; Williams K; Williams O; Kioussis D
    J Immunol; 1999 Aug; 163(3):1162-9. PubMed ID: 10415010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of disabling T-cell activation and inhibiting T-cell-mediated immunopathology reveals a possible inverse agonist activity of CD4 peptidomimetics.
    Horie T; Shen Y; Kajino K; Gaubin M; Bonomi G; Mani JC; Berezov A; Piatier-Tonneau D; Guardiola J; Hillard B; Rostami A; Greene M; Murali R
    Exp Mol Pathol; 2002 Oct; 73(2):93-103. PubMed ID: 12231211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo biotinylation of the major histocompatibility complex (MHC) class II/peptide complex by coexpression of BirA enzyme for the generation of MHC class II/tetramers.
    Yang J; Jaramillo A; Shi R; Kwok WW; Mohanakumar T
    Hum Immunol; 2004 Jul; 65(7):692-9. PubMed ID: 15301857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited plasticity in T cell recognition of modified T cell receptor contact residues in MHC class II bound peptides.
    de Haan EC; Wagenaar-Hilbers JP; Liskamp RM; Moret EE; Wauben MH
    Mol Immunol; 2005 Feb; 42(3):355-64. PubMed ID: 15589324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.